Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.32

+0.7%

Nov 5 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (210)	2/23/1999 9:59:00 PM
From: scaram(o)uche	Read Replies (2) of 1475

Damn...... exchange2000.com Not only is BGEN committed to more clinicals for anti-CD40L than MEDI is for 507, they're already thinking ahead for meeting the huge demand. Again I ask..... is it time for MEDI to sublicense 507 for indications that they just can't bite off?????? We could win all the battles and lose the war. I spoke with Dr. Patrick Trown at ONXX over a year ago about the induction of tolerance to adenovirus, and suggested that he contact BTRN. When I spoke recently with Dr. Ali Fattaey, Vice President Discovery Research, he indicated that they were interested in the concept, but that they were focused on anti-CD40L. Given, there is no data that I know of to indicate that 507 inhibits antibody responses, or inhibits them to the degree that anti-CD40L does. However, why do I get the idea that this product does not have an effective champion????????

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next